Drug
Sabatolimab clinical trials
Also written MBG453.
How studies write it
Studies that test it under each name
Studies by the year they started
12 studies that test it; most in 2020 (4)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2019 | 2 |
| 2020 | 4 |
| 2021 | 2 |
| 2022 | 2 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 9 · Other 3
Novartis Pharmaceuticals (9) · M.D. Anderson Cancer Center (1) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1) · Massachusetts General Hospital (1)
Often tested with
Tested in the same studies.
Azacitidine (3) · Venetoclax (3) · Decitabine (2) · Spartalizumab (2) · Nisevokitug (2) · Canakinumab (1)
Related medicines
As reviewed, each with the page that says it.
Studies
Open first, then newest update. How each study uses sabatolimab is read from its arms, and is right about nine times in ten.
Testing it · 12
- MBG453 in Lower Risk MDSTerminatedPhase 2Massachusetts General HospitalNCT04823624Written as MBG453
- Trial of Anti-Tim-3 in Combination With Anti-PD-1 and SRS in Recurrent GBMCompletedPhase 1Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT03961971Written as MBG453
- ALLG AMLM26 INTERCEPT (Investigating Novel Therapy to Target Early Relapse and Clonal Evolution as Pre-emptive Therapy in AML): A Multi-arm, Precision-based, Recursive, Platform TrialActive, not recruitingPhase 1/2M.D. Anderson Cancer CenterNCT06664879Written as MBG-453 + Azacitidine
- A Study of MBG453 in Combination With Azacitidine and Venetoclax in AML Patients Unfit for ChemotherapyTerminatedPhase 2Novartis PharmaceuticalsNCT04150029Written as MBG453
- Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2)TerminatedPhase 3Novartis PharmaceuticalsNCT04266301Written as Sabatolimab
- A Study of MBG453 in Combination With Hypomethylating Agents in Subjects With IPSS-R Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS).TerminatedPhase 2Novartis PharmaceuticalsNCT03946670Written as MBG453
- STIMULUS MDS-US : Sabatolimab Added to HMA in Higher Risk MDSTerminatedPhase 2Novartis PharmaceuticalsNCT04878432Written as MBG453
- HDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS)TerminatedPhase 1Novartis PharmaceuticalsNCT03940352Written as MBG453
- Phase Ib Study of Select Drug Combinations in Patients With Lower Risk MDSTerminatedPhase 1Novartis PharmaceuticalsNCT04810611Written as MBG453
- A Study of Sabatolimab in Combination With Azacitidine and Venetoclax in High or Very High Risk MDS ParticipantsTerminatedPhase 2Novartis PharmaceuticalsNCT04812548Written as sabatolimab
- Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDSCompletedPhase 1Novartis PharmaceuticalsNCT03066648Written as MBG453
- Study of Select Combinations in Adults With MyelofibrosisWithdrawnPhase 1Novartis PharmaceuticalsNCT04283526Written as MBG453
Given in every arm · 5 — sabatolimab is usual care beside what is tested
- Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.Active, not recruitingPhase 2Novartis PharmaceuticalsNCT05201066Written as sabatolimab
- Sabatolimab as a Treatment for Patients With Acute Myeloid Leukemia and Presence of Measurable Residual Disease After Allogeneic Stem Cell Transplantation.TerminatedPhase 1/2Novartis PharmaceuticalsNCT04623216Written as Sabatolimab
- Platform Study of Novel Ruxolitinib Combinations in Myelofibrosis PatientsTerminatedPhase 1/2Novartis PharmaceuticalsNCT04097821Written as Sabatolimab
- A Study of Sabatolimab and Magrolimab-based Treatment in AML or Higher Risk MDS ParticipantsWithdrawnPhase 1/2Novartis PharmaceuticalsNCT05367401Written as Sabatolimab
- Phase I-Ib/II Study of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced MalignanciesTerminatedPhase 1/2Novartis PharmaceuticalsNCT02608268Written as MBG453
Codes
What other systems call sabatolimab · ClinicalTrials.gg INT001969
- MeSH (NLM) C000723550sabatolimabOne source ClinicalTrials.gov
- UNII (FDA) 3L7R886Y06SABATOLIMABOne source FDA
- NCI Thesaurus C124850SabatolimabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000723550 | sabatolimab | One source ClinicalTrials.gov |
| UNII (FDA) | 3L7R886Y06 | SABATOLIMAB | One source FDA |
| NCI Thesaurus | C124850 | Sabatolimab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.